The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.

@article{Rizoli2006TheER,
  title={The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.},
  author={Sandro Baletotti Rizoli and Talat Chughtai},
  journal={Expert opinion on biological therapy},
  year={2006},
  volume={6 1},
  pages={
          73-81
        }
}
Recombinant activated Factor VII (rFVIIa; eptacog alpha [activated], NovoSeven) is currently used for the management of a subgroup of haemophilia patients with inhibitors to Factors VIII or IX, and is under investigation as an adjuvant therapy for critical bleeding from other causes, including trauma. rFVIIa has a mode of action founded on physiological coagulation processes, and causes localised haemostasis at injury sites, both spontaneous and traumatic, with the capacity to correct the… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS